Mereo BioPharma's (LON:MPH) Denise Scots-Knight explains why she's confident in the potential of their lead drug setrusumab despite it not meeting its primary endpoint in a recent Phase 2b study.
The drug's being developed as a treatment for osteogenesis imperfecta which is also known as brittle bone disease.